Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Yee discussed how the data show a benefit in this hard-to-treat population, similarly to the heterogeneous FSGS group.

Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS

Zand discussed interim 12-month findings from an open-label, phase 2 trial currently ongoing for patients with refractory primary focal segmental glomerulosclerosis.

Ladan Zand, MD: Obinutuzumab a Promising Option for Refractory, Primary FSGS

A posthoc analysis of the DUPLEX trial suggests patients with genetic FSGS may experience a more pronounced and sustained antiproteinuric response with sparsentan.

DUPLEX: Sparsentan Could Offer Greater Benefit in Genetic FSGS

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Focal Segmental Glomerulosclerosis